Urgent.News

What's breaking now, across thousands of outlets.

Health & Medicine

Roche's Wilserdly-Everolimus Gets FDA Approval For ESR1-Mutated Advanced Breast Cancer

(RTTNews) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Read the original at nasdaq.com →

More in Health & Medicine

More from Tuesday 17 November →